首页 > 最新文献

Tumori最新文献

英文 中文
Prevalence of breast cancer in ovarian cancer patients and its impact on patient survival: An analysis of the surveillance, epidemiology, and end results data.
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-03-12 DOI: 10.1177/03008916251323224
Ni Zhang, Wanfang Zhang, Yu Liu, Hui Qiu, Qiuji Wu

Background: Patients with high-grade serous ovarian carcinoma (HGSOC) often have a personal and/or family history of breast cancers. However, the clinical association and underlying molecular interaction between breast cancer and HGSOC is not well understood. In this study, the clinical characteristics and outcomes of HGSOC patients with or without breast cancer were compared.

Methods: Eligible patient information was extracted from the Surveillance, Epidemiology, and End Results database. Kaplan-Meier and Cox proportional hazards regression models were used to determine survival outcomes and prognostic factors.

Results: A total of 3065 HGSOC (ICD-O-3 code 8461/3) patients were identified from 1975 to 2020, among whom 239 (9.56%) had co-existing breast cancers. HGSOC with breast cancers tended to have more stage I-II ovarian cancer (20.92% vs 13.79%), less metastatic diseases (25.1% vs 32.13%) and had a higher probability of undergoing surgery (94.1% vs 87.9%). The overall survival of HGSOC patients with breast cancer was better than that of patients without breast cancer (HR = 0.77, 95% CI 0.65 to 0.91; P = 0.0015). Further, patients who developed ovarian cancer before breast cancer had better overall survival than those who developed breast cancer before or simultaneously with ovarian cancer (HR = 0.35, 95% CI 0.23 to 0.52; P < 0.001).

Conclusion: HGSOC combined with breast cancer is a common phenomenon. HGSOC patients with breast cancer, especially those diagnosed with ovarian cancer before breast cancer have a better prognosis. Further validation is warranted and more genetic and mechanistical study is needed.

{"title":"Prevalence of breast cancer in ovarian cancer patients and its impact on patient survival: An analysis of the surveillance, epidemiology, and end results data.","authors":"Ni Zhang, Wanfang Zhang, Yu Liu, Hui Qiu, Qiuji Wu","doi":"10.1177/03008916251323224","DOIUrl":"https://doi.org/10.1177/03008916251323224","url":null,"abstract":"<p><strong>Background: </strong>Patients with high-grade serous ovarian carcinoma (HGSOC) often have a personal and/or family history of breast cancers. However, the clinical association and underlying molecular interaction between breast cancer and HGSOC is not well understood. In this study, the clinical characteristics and outcomes of HGSOC patients with or without breast cancer were compared.</p><p><strong>Methods: </strong>Eligible patient information was extracted from the Surveillance, Epidemiology, and End Results database. Kaplan-Meier and Cox proportional hazards regression models were used to determine survival outcomes and prognostic factors.</p><p><strong>Results: </strong>A total of 3065 HGSOC (ICD-O-3 code 8461/3) patients were identified from 1975 to 2020, among whom 239 (9.56%) had co-existing breast cancers. HGSOC with breast cancers tended to have more stage I-II ovarian cancer (20.92% vs 13.79%), less metastatic diseases (25.1% vs 32.13%) and had a higher probability of undergoing surgery (94.1% vs 87.9%). The overall survival of HGSOC patients with breast cancer was better than that of patients without breast cancer (HR = 0.77, 95% CI 0.65 to 0.91; <i>P</i> = 0.0015). Further, patients who developed ovarian cancer before breast cancer had better overall survival than those who developed breast cancer before or simultaneously with ovarian cancer (HR = 0.35, 95% CI 0.23 to 0.52; <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>HGSOC combined with breast cancer is a common phenomenon. HGSOC patients with breast cancer, especially those diagnosed with ovarian cancer before breast cancer have a better prognosis. Further validation is warranted and more genetic and mechanistical study is needed.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251323224"},"PeriodicalIF":2.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations between vascular endothelial growth factor polymorphisms and response to 5-FU-based pharmaceutical therapy in esophageal squamous cell carcinoma: A meta-analysis.
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-26 DOI: 10.1177/03008916251322057
Yonghui Li, Qiang Guo, Haibo Wang, Ruiyao Wang, WenLi Kang, Cheng Long Zhang, Duo Zhang, Kuo Xiao, ZhenQing Sun

Background and aims: Vascular endothelial growth factor (VEGF) gene polymorphisms are associated with the response to pharmaceutical therapy in many cancers. This study aimed to investigate the effects of VEGF gene polymorphisms in esophageal squamous cell carcinoma patients receiving pharmaceutical therapy.

Methods: This literature-based meta-analysis was performed with keywords related to VEGF gene polymorphisms and clinical response in esophageal squamous carcinoma patients receiving pharmaceutical therapy (including 5-FU, cisplatin, oxaliplatin, and calcium folinate). After a series of bias grading analyses and DerSimonian-Laird method analysis, odds ratios and 95% confidence intervals were calculated to examine the potential relationships. Sensitivity and subgroup analyses were subsequently performed to determine the major causes of heterogeneity.

Results: Heterogeneity was dramatically reduced after the removal of one study from the analysis (I2 = 37%, P = 0.19). The remaining studies involved 5-FU-based treatment. The presence of VEGF G-1154A and VEGF-634C/G was found to be correlated with patient response to 5-FU/CDDP-based treatment, whereas VEGF-2549I/D was correlated with response to 5-FU/oxaliplatin-based treatment, and VEGF-936C/T was associated with both 5-FU/CDDP- and 5-FU/oxaliplatin-based treatment response.

Conclusion: VEGF gene polymorphisms affect the response of esophageal squamous carcinoma patients receiving pharmaceutical therapy, especially 5-FU-based treatments.

{"title":"Associations between vascular endothelial growth factor polymorphisms and response to 5-FU-based pharmaceutical therapy in esophageal squamous cell carcinoma: A meta-analysis.","authors":"Yonghui Li, Qiang Guo, Haibo Wang, Ruiyao Wang, WenLi Kang, Cheng Long Zhang, Duo Zhang, Kuo Xiao, ZhenQing Sun","doi":"10.1177/03008916251322057","DOIUrl":"https://doi.org/10.1177/03008916251322057","url":null,"abstract":"<p><strong>Background and aims: </strong>Vascular endothelial growth factor (<i>VEGF</i>) gene polymorphisms are associated with the response to pharmaceutical therapy in many cancers. This study aimed to investigate the effects of <i>VEGF</i> gene polymorphisms in esophageal squamous cell carcinoma patients receiving pharmaceutical therapy.</p><p><strong>Methods: </strong>This literature-based meta-analysis was performed with keywords related to <i>VEGF</i> gene polymorphisms and clinical response in esophageal squamous carcinoma patients receiving pharmaceutical therapy (including 5-FU, cisplatin, oxaliplatin, and calcium folinate). After a series of bias grading analyses and DerSimonian-Laird method analysis, odds ratios and 95% confidence intervals were calculated to examine the potential relationships. Sensitivity and subgroup analyses were subsequently performed to determine the major causes of heterogeneity.</p><p><strong>Results: </strong>Heterogeneity was dramatically reduced after the removal of one study from the analysis (<i>I</i><sup>2</sup> = 37%, <i>P</i> = 0.19). The remaining studies involved 5-FU-based treatment. The presence of VEGF G-1154A and VEGF-634C/G was found to be correlated with patient response to 5-FU/CDDP-based treatment, whereas VEGF<i>-</i>2549I/D was correlated with response to 5-FU/oxaliplatin-based treatment, and VEGF-936C/T was associated with both 5-FU/CDDP- and 5-FU/oxaliplatin-based treatment response.</p><p><strong>Conclusion: </strong><i>VEGF</i> gene polymorphisms affect the response of esophageal squamous carcinoma patients receiving pharmaceutical therapy, especially 5-FU-based treatments.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251322057"},"PeriodicalIF":2.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards a better registration of neuroendocrine neoplasms: The results of the Italian retrospective population-based study.
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-26 DOI: 10.1177/03008916251317128
Annalisa Trama, Francesco Cuccaro, Domenico Damiani, Alice Bernasconi, Francesco Panzuto, Nicola Fazio, Simona Carone, Maria Giovanna Burgio Lo Monaco, Rossella Bruni, Adele Caldarella, Annalisa Roselli, Barbara Cortini, Rosalba Amodio, Walter Mazzucco, Silvia Leite, Chiara Lupi, Maddalena Baracco, Eva Carpin, Antonella Dal Cin, Annarita Fiore, Laura Memo, Stefano Guzzinati, Antonietta Alfia Maria Torrisi, Antonina Torrisi, Margherita Ferrante, Maria Teresa Pesce, Alessandra Sessa, Antonietta Minichino, Nadia Di Pascale, Maria Francesca Vitale, Mario Fusco, Ilaria Girolami, Massimo Milione, Fabrizio Stracci

Background: The increasing incidence, rapidly evolving classification, rarity and heterogeneity of neuroendocrine neoplasms (NENs) pose challenges to NEN registration including difficulty in distinguishing neuroendocrine carcinoma (NEC) and neuroendocrine tumours (NETs). Thus, in Italy a higher NEC incidence was reported. Focusing on gastroenteropancreatic (GEP) NEN, we aimed to review GEP NEN, and in particular cases of neuroendocrine carcinoma, not otherwise specified (NOS) and estimate the incidence of NEN, NET and NEC of the GEP.

Methods: We launched a pilot study examining cases of neuroendocrine carcinomas NOS (ICD-O3 code 8246) of GEP incidents in the years 2012-2020. Cancer registries (CRs) reviewed information included in the pathology report regarding differentiation and tumour cells proliferation to decide whether to confirm the case as neuroendocrine carcinoma NOS or register it as NET or NEC. After the review, we estimated the GEP NEN, NET and NEC incidence.

Results: Nine CRs contributed to the pilot study. After review, in all CRs, only 31% of GEP NOS neuroendocrine carcinomas were confirmed; 50% were recoded as NETs, and approximately 17% of cases were non-NENs. The IR of GEP NENs was 2.99/100,000, and the incidence of NETs was higher than that of NECs.

Conclusion: After the review, the incidence of GEP NEN, NET and NEC in the eight Italian CRs involved was comparable to that reported in other European countries.

Impact: Our results confirmed that heterogeneity of cancer registries in the registration of NEN requires collaborative work to define and promote a standard definition to be extended to all Italian registries.

{"title":"Towards a better registration of neuroendocrine neoplasms: The results of the Italian retrospective population-based study.","authors":"Annalisa Trama, Francesco Cuccaro, Domenico Damiani, Alice Bernasconi, Francesco Panzuto, Nicola Fazio, Simona Carone, Maria Giovanna Burgio Lo Monaco, Rossella Bruni, Adele Caldarella, Annalisa Roselli, Barbara Cortini, Rosalba Amodio, Walter Mazzucco, Silvia Leite, Chiara Lupi, Maddalena Baracco, Eva Carpin, Antonella Dal Cin, Annarita Fiore, Laura Memo, Stefano Guzzinati, Antonietta Alfia Maria Torrisi, Antonina Torrisi, Margherita Ferrante, Maria Teresa Pesce, Alessandra Sessa, Antonietta Minichino, Nadia Di Pascale, Maria Francesca Vitale, Mario Fusco, Ilaria Girolami, Massimo Milione, Fabrizio Stracci","doi":"10.1177/03008916251317128","DOIUrl":"https://doi.org/10.1177/03008916251317128","url":null,"abstract":"<p><strong>Background: </strong>The increasing incidence, rapidly evolving classification, rarity and heterogeneity of neuroendocrine neoplasms (NENs) pose challenges to NEN registration including difficulty in distinguishing neuroendocrine carcinoma (NEC) and neuroendocrine tumours (NETs). Thus, in Italy a higher NEC incidence was reported. Focusing on gastroenteropancreatic (GEP) NEN, we aimed to review GEP NEN, and in particular cases of neuroendocrine carcinoma, not otherwise specified (NOS) and estimate the incidence of NEN, NET and NEC of the GEP.</p><p><strong>Methods: </strong>We launched a pilot study examining cases of neuroendocrine carcinomas NOS (ICD-O3 code 8246) of GEP incidents in the years 2012-2020. Cancer registries (CRs) reviewed information included in the pathology report regarding differentiation and tumour cells proliferation to decide whether to confirm the case as neuroendocrine carcinoma NOS or register it as NET or NEC. After the review, we estimated the GEP NEN, NET and NEC incidence.</p><p><strong>Results: </strong>Nine CRs contributed to the pilot study. After review, in all CRs, only 31% of GEP NOS neuroendocrine carcinomas were confirmed; 50% were recoded as NETs, and approximately 17% of cases were non-NENs. The IR of GEP NENs was 2.99/100,000, and the incidence of NETs was higher than that of NECs.</p><p><strong>Conclusion: </strong>After the review, the incidence of GEP NEN, NET and NEC in the eight Italian CRs involved was comparable to that reported in other European countries.</p><p><strong>Impact: </strong>Our results confirmed that heterogeneity of cancer registries in the registration of NEN requires collaborative work to define and promote a standard definition to be extended to all Italian registries.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251317128"},"PeriodicalIF":2.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ESCO1 as a novel predictive biomarker and potential therapeutic target in renal cell carcinoma.
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-16 DOI: 10.1177/03008916241311395
Yang Teng, Sixiu Li, Zhifang Zhang, Weinan Wang, Xueli Yuan, Jianye Li, Shiying Zhang, Yanhong Cui

Background: Establishment of sister chromatid cohesion N-acetyltransferase 1 (ESCO1) plays an important role in mitosis and is involved in tumor progression of human bladder and prostate cancer. However, its pathological effects on renal cell cancer (RCC) remain unknown. Here, we aimed to assess the impact of ESCO1 down-regulation in RCC cells and explore its role as potential prognosis biomarker for RCC.

Methods: This is a retrospective study. Tumor samples from 263 RCC patients were collected, and survival data were analyzed to detect the relationship between ESCO1 expression and patient survival. For mechanistic exploration, the impact of silence ESCO1 on proliferation, migration and apoptosis were studied in ESCO1-knockdown RCC cells.

Results: Significantly over-expression of ESCO1 was observed in renal tumor tissues. ESCO1 expression was related to the malignant degree and a high expression was associated with unfavorable prognosis in RCC patients. Moreover, down-regulation of ESCO1 attenuated cell proliferation and migration. The flow cytometry assay revealed that the knockdown of ESCO1 inhibited RCC cells from entering the G1 phase.

Conclusions: The increased ESCO1 expression in renal tumor tissues might be a useful biomarker for prognosis of RCC patients. Knockdown of ESCO1 undermined proliferation, migration of renal cancer cells, and induced the apoptosis of renal cancer cells.

{"title":"ESCO1 as a novel predictive biomarker and potential therapeutic target in renal cell carcinoma.","authors":"Yang Teng, Sixiu Li, Zhifang Zhang, Weinan Wang, Xueli Yuan, Jianye Li, Shiying Zhang, Yanhong Cui","doi":"10.1177/03008916241311395","DOIUrl":"https://doi.org/10.1177/03008916241311395","url":null,"abstract":"<p><strong>Background: </strong>Establishment of sister chromatid cohesion N-acetyltransferase 1 (ESCO1) plays an important role in mitosis and is involved in tumor progression of human bladder and prostate cancer. However, its pathological effects on renal cell cancer (RCC) remain unknown. Here, we aimed to assess the impact of ESCO1 down-regulation in RCC cells and explore its role as potential prognosis biomarker for RCC.</p><p><strong>Methods: </strong>This is a retrospective study. Tumor samples from 263 RCC patients were collected, and survival data were analyzed to detect the relationship between ESCO1 expression and patient survival. For mechanistic exploration, the impact of silence ESCO1 on proliferation, migration and apoptosis were studied in ESCO1-knockdown RCC cells.</p><p><strong>Results: </strong>Significantly over-expression of ESCO1 was observed in renal tumor tissues. ESCO1 expression was related to the malignant degree and a high expression was associated with unfavorable prognosis in RCC patients. Moreover, down-regulation of ESCO1 attenuated cell proliferation and migration. The flow cytometry assay revealed that the knockdown of ESCO1 inhibited RCC cells from entering the G1 phase.</p><p><strong>Conclusions: </strong>The increased ESCO1 expression in renal tumor tissues might be a useful biomarker for prognosis of RCC patients. Knockdown of ESCO1 undermined proliferation, migration of renal cancer cells, and induced the apoptosis of renal cancer cells.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916241311395"},"PeriodicalIF":2.0,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploratory analysis of the professional quality of life in an Italian radiotherapy department: The role of empathy and alexithymia.
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-09 DOI: 10.1177/03008916251317093
Tiziana Burla, Mattia Zaffaroni, Giulia Marvaso, Ketti Mazzocco, Gabriele Galli, Maria Giulia Vincini, Federico Mastroleo, Massimo Sarra Fiore, Gabriella Pravettoni, Barbara Alicja Jereczek-Fossa

Purpose: Professional quality of life (QoL) is crucial for healthcare workers as it affects performance at work and interaction with patients, but little is known about stressors influencing radiation oncology professionals. The present study aims to explore the professional QoL of radiation oncologists (ROs) and radiation therapists (RTTs) in an Italian radiotherapy department and to report data about the possible impact of personality factors, such as alexithymia and empathy.

Material and methods: Participants filled out three validated questionnaires measuring the professional QoL, alexithymia, and empathy: (i) Professional Quality of Life Scale (ProQOL); (ii) Toronto Alexithymia Scale (TAS-20); (iii) Interpersonal Reactivity Index (IRI). Correlation, regression analyses and non-parametric tests were run.

Results: A total of 48 professionals completed the survey (66.7% ROs, 33.3% RTTs). Considering the ProQOL dimensions, moderate levels of risk for burnout (BO) and secondary traumatic stress (STS) were found. BO was found to be predictive by TAS-20 total score (β=.37, p=.010), while STS resulted to be predictive by TAS-20 total score (β=.54, p <.001) and IRI Empathic Concern subscale (β=.45, p <.001). No significant differences were found between ROs and RTTs for all the considered variables, except for TAS-20 total score (p=.032), higher for RTTs.

Conclusions: Results showed no evidence of high risk of burnout and no intrinsic differences regarding the professional QoL between ROs and RTTs. Findings suggest a significant role of alexithymia and empathy predicting professional QoL. These results underscore the importance of promoting a positive work environment and emotional competencies to prevent high stress levels.

{"title":"Exploratory analysis of the professional quality of life in an Italian radiotherapy department: The role of empathy and alexithymia.","authors":"Tiziana Burla, Mattia Zaffaroni, Giulia Marvaso, Ketti Mazzocco, Gabriele Galli, Maria Giulia Vincini, Federico Mastroleo, Massimo Sarra Fiore, Gabriella Pravettoni, Barbara Alicja Jereczek-Fossa","doi":"10.1177/03008916251317093","DOIUrl":"https://doi.org/10.1177/03008916251317093","url":null,"abstract":"<p><strong>Purpose: </strong>Professional quality of life (QoL) is crucial for healthcare workers as it affects performance at work and interaction with patients, but little is known about stressors influencing radiation oncology professionals. The present study aims to explore the professional QoL of radiation oncologists (ROs) and radiation therapists (RTTs) in an Italian radiotherapy department and to report data about the possible impact of personality factors, such as alexithymia and empathy.</p><p><strong>Material and methods: </strong>Participants filled out three validated questionnaires measuring the professional QoL, alexithymia, and empathy: (i) Professional Quality of Life Scale (ProQOL); (ii) Toronto Alexithymia Scale (TAS-20); (iii) Interpersonal Reactivity Index (IRI). Correlation, regression analyses and non-parametric tests were run.</p><p><strong>Results: </strong>A total of 48 professionals completed the survey (66.7% ROs, 33.3% RTTs). Considering the ProQOL dimensions, moderate levels of risk for burnout (BO) and secondary traumatic stress (STS) were found. BO was found to be predictive by TAS-20 total score (β=.37, <i>p</i>=.010), while STS resulted to be predictive by TAS-20 total score (β=.54, <i>p</i> <.001) and IRI Empathic Concern subscale (β=.45, <i>p</i> <.001). No significant differences were found between ROs and RTTs for all the considered variables, except for TAS-20 total score (<i>p</i>=.032), higher for RTTs.</p><p><strong>Conclusions: </strong>Results showed no evidence of high risk of burnout and no intrinsic differences regarding the professional QoL between ROs and RTTs. Findings suggest a significant role of alexithymia and empathy predicting professional QoL. These results underscore the importance of promoting a positive work environment and emotional competencies to prevent high stress levels.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251317093"},"PeriodicalIF":2.0,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CT-based radiomics: A potential indicator of KRAS mutation in pulmonary adenocarcinoma.
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-02 DOI: 10.1177/03008916251314659
Menna Allah Mahmoud, Sijun Wu, Ruihua Su, Yuling Liufu, Yanhua Wen, Xiaohuan Pan, Yubao Guan

Purpose: This study aimed to validate a CT-based radiomics signature for predicting Kirsten rat sarcoma (KRAS) mutation status in lung adenocarcinoma (LADC).

Materials and methods: A total of 815 LADC patients were included. Radiomics features were extracted from non-contrast-enhanced CT (NECT) and contrast-enhanced CT (CECT) images using Pyradiomics. CT-based radiomics were combined with clinical features to distinguish KRAS mutation status. Four feature selection methods and four deep learning classifiers were employed. Data was split into 70% training and 30% test sets, with SMOTE addressing imbalance in the training set. Model performance was evaluated using AUC, accuracy, precision, F1 score, and recall.

Results: The analysis revealed that 10.4% of patients showed KRAS mutations. The study extracted 1061 radiomics features and combined them with 17 clinical features. After feature selection, two signatures were constructed using top 10, 20, and 50 features. The best performance was achieved using Multilayer Perceptron with 20 features. CECT, it showed 66% precision, 76% recall, 69% F1-score, 84% accuracy, and AUC of 93.3% and 87.4% for train and test sets, respectively. For NECT, accuracy was 85% and 82%, with AUC of 90.7% and 87.6% for train and test sets, respectively.

Conclusions: CT-based radiomics signature is a noninvasive method that can predict KRAS mutation status of LADC when mutational profiling is unavailable.

{"title":"CT-based radiomics: A potential indicator of KRAS mutation in pulmonary adenocarcinoma.","authors":"Menna Allah Mahmoud, Sijun Wu, Ruihua Su, Yuling Liufu, Yanhua Wen, Xiaohuan Pan, Yubao Guan","doi":"10.1177/03008916251314659","DOIUrl":"https://doi.org/10.1177/03008916251314659","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to validate a CT-based radiomics signature for predicting Kirsten rat sarcoma (KRAS) mutation status in lung adenocarcinoma (LADC).</p><p><strong>Materials and methods: </strong>A total of 815 LADC patients were included. Radiomics features were extracted from non-contrast-enhanced CT (NECT) and contrast-enhanced CT (CECT) images using Pyradiomics. CT-based radiomics were combined with clinical features to distinguish KRAS mutation status. Four feature selection methods and four deep learning classifiers were employed. Data was split into 70% training and 30% test sets, with SMOTE addressing imbalance in the training set. Model performance was evaluated using AUC, accuracy, precision, F1 score, and recall.</p><p><strong>Results: </strong>The analysis revealed that 10.4% of patients showed KRAS mutations. The study extracted 1061 radiomics features and combined them with 17 clinical features. After feature selection, two signatures were constructed using top 10, 20, and 50 features. The best performance was achieved using Multilayer Perceptron with 20 features. CECT, it showed 66% precision, 76% recall, 69% F1-score, 84% accuracy, and AUC of 93.3% and 87.4% for train and test sets, respectively. For NECT, accuracy was 85% and 82%, with AUC of 90.7% and 87.6% for train and test sets, respectively.</p><p><strong>Conclusions: </strong>CT-based radiomics signature is a noninvasive method that can predict KRAS mutation status of LADC when mutational profiling is unavailable.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916251314659"},"PeriodicalIF":2.0,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between clinical factors and the choice of palliative care setting among cancer patients: A post-hoc analysis of a cohort study. 临床因素与癌症患者选择姑息治疗环境之间的关系:一项队列研究的事后分析。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-17 DOI: 10.1177/03008916241301286
Oscar Corli, Luca Porcu, Cristina Bosetti, Angela Recchia, Silvia De Giorgi, Giada Lonati, Barbara Rizzi

Introduction: In the literature, the data about the factors related to the choice of the setting at patient's first palliative care admission visit are scanty. In fact it seems that the choice between home or hospice care is mainly based on the opinions and needs of patients, families and physicians. This study aims to address the association between the clinical factors detected at the first palliative visit in advanced cancer patients and the choice of palliative care setting (i.e., hospice or home care).

Methods: This is a monocentric, prospective cohort study. A total of 1811 consecutive patients with advanced cancer, admitted to the VIDAS Palliative Care service (hospice/ home care), Milan, Italy in 2018-2020 were included.

Results: In the univariate analysis, several clinical comorbidities and physiological deficits were associated with hospice admittance; while patients with more severe symptoms of anxiety, asthenia, depression, and pain were associated with home care admittance. In the multivariate logistic analysis, six clinical factors were associated with the risk of hospice admission: anxiety (OR 0.16), brain metastases (OR 1.67), severe sleep-wake rhythm upset (OR 1.79), bone/vertebral fractures (OR 2.12), intestinal occlusion or sub-occlusion (OR 2.16), and cachexia (OR 2.25). The multivariate cluster analysis confirmed the link observed with the previous statistical analyses.

Conclusion: The results of this analysis showed that some clinical factors were closely related to the chosen palliative care setting and should be taken into consideration a priori to deciding the most appropriate place of care.

引言:在文献中,关于患者第一次姑息治疗入院时环境选择相关因素的数据很少。事实上,在家庭或临终关怀之间的选择似乎主要是基于患者,家属和医生的意见和需求。本研究旨在探讨晚期癌症患者第一次姑息治疗访视时所检测到的临床因素与选择姑息治疗环境(即安宁疗护或居家疗护)之间的关系。方法:这是一项单中心前瞻性队列研究。2018-2020年共纳入1811名连续入住意大利米兰VIDAS姑息治疗服务(临终关怀/家庭护理)的晚期癌症患者。结果:在单因素分析中,几种临床合并症和生理缺陷与安宁疗护入院有关;而焦虑、虚弱、抑郁和疼痛症状较严重的患者则与家庭护理有关。在多变量logistic分析中,六个临床因素与安宁疗护入院风险相关:焦虑(OR 0.16)、脑转移(OR 1.67)、严重睡眠-觉醒节律紊乱(OR 1.79)、骨/椎体骨折(OR 2.12)、肠道闭塞或亚闭塞(OR 2.16)和恶病质(OR 2.25)。多变量聚类分析证实了与之前统计分析观察到的联系。结论:本分析结果显示,一些临床因素与选择姑息治疗环境密切相关,在决定最合适的护理场所时应优先考虑这些因素。
{"title":"Association between clinical factors and the choice of palliative care setting among cancer patients: A post-hoc analysis of a cohort study.","authors":"Oscar Corli, Luca Porcu, Cristina Bosetti, Angela Recchia, Silvia De Giorgi, Giada Lonati, Barbara Rizzi","doi":"10.1177/03008916241301286","DOIUrl":"10.1177/03008916241301286","url":null,"abstract":"<p><strong>Introduction: </strong>In the literature, the data about the factors related to the choice of the setting at patient's first palliative care admission visit are scanty. In fact it seems that the choice between home or hospice care is mainly based on the opinions and needs of patients, families and physicians. This study aims to address the association between the clinical factors detected at the first palliative visit in advanced cancer patients and the choice of palliative care setting (i.e., hospice or home care).</p><p><strong>Methods: </strong>This is a monocentric, prospective cohort study. A total of 1811 consecutive patients with advanced cancer, admitted to the VIDAS Palliative Care service (hospice/ home care), Milan, Italy in 2018-2020 were included.</p><p><strong>Results: </strong>In the univariate analysis, several clinical comorbidities and physiological deficits were associated with hospice admittance; while patients with more severe symptoms of anxiety, asthenia, depression, and pain were associated with home care admittance. In the multivariate logistic analysis, six clinical factors were associated with the risk of hospice admission: anxiety (OR 0.16), brain metastases (OR 1.67), severe sleep-wake rhythm upset (OR 1.79), bone/vertebral fractures (OR 2.12), intestinal occlusion or sub-occlusion (OR 2.16), and cachexia (OR 2.25). The multivariate cluster analysis confirmed the link observed with the previous statistical analyses.</p><p><strong>Conclusion: </strong>The results of this analysis showed that some clinical factors were closely related to the chosen palliative care setting and should be taken into consideration a priori to deciding the most appropriate place of care.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"79-87"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fertility and abortion: A population-based comparison between women with cancer and those in childbearing age. 生育和堕胎:以人口为基础的癌症妇女和育龄妇女的比较。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-02 DOI: 10.1177/03008916241298810
Alice Maraschini, Edoardo Corsi Decenti, Serena Donati, Silvia Francisci, Tania Lopez, Rosalba Amodio, Fortunato Bianconi, Emanuela Bovo, Rossella Bruni, Marine Castaing, Claudia Cirilli, Rosa Pasqualina De Vincenzo, Giuseppe Furgiuele, Linda Guarda, Silvia Iacovacci, Lucia Mangone, Walter Mazzucco, Anna Melcarne, Elisabetta Merlo, Michael Mian, Giuseppe Sampietro, Giovanni Scambia, Tiziana Scuderi, Ausilia Sferrazza, Fabrizio Stracci, Antonina Torrisi, Vito Trojano, Maria Francesca Vitale, Daniela Pierannunzio

Objectives: Concurrence of pregnancy and cancer diagnosis is increasingly frequent in Italy. The study aimed to compare women with pregnancy-associated cancers (PACs) to those of childbearing age, focusing on fertility, induced abortion, and miscarriage.

Methods: The population-based study included women aged 15-49 years, both with and without PAC, who were residents in the area covered by the 19 participating Cancer Registries between 2003 and 2015 and identified by individual deterministic linkage with the Hospital Discharge Database.

Results: Overall, 2,218,139 obstetrics hospitalizations occurred, covering delivery (75%), induced abortion (14%), and miscarriage (11%). Among 2409 women with PAC, 69% gave birth, 16% had an induced abortion and 15% a miscarriage. Compared with the reference population, the fertility rate in women with PACs was steadily lower (mean values 25.7/1000 vs 37.7/1000), while induced abortion (from 359/1000 - SRR 1.99, 95%CI 1.32-3.00 - in 2003 to 147/1000 - SRR 1.11, 95%CI 0.59-2.09 - in 2015) and miscarriage ratios exhibited a decreasing trend.

Conclusion: These results are consistent with international literature and are probably due to advancements in diagnostic and therapeutic opportunities. This is the first Italian population-based study analysing fertility and pregnancy outcomes among women with PAC based on a reliable information on cancer diagnosis.

目的:妊娠和癌症同时诊断在意大利越来越常见。该研究旨在比较患有妊娠相关癌症(PACs)的妇女与育龄妇女,重点关注生育能力、人工流产和流产。方法:以人群为基础的研究纳入了年龄在15-49岁之间的女性,有或没有PAC,她们是2003年至2015年期间19个参与癌症登记处所涵盖的地区的居民,并通过与医院出院数据库的个体确定性联系确定。结果:总体而言,发生了2,218,139例产科住院,包括分娩(75%)、人工流产(14%)和流产(11%)。2409名PAC患者中,69%分娩,16%人工流产,15%流产。与参考人群相比,PACs妇女的生育率稳步下降(平均值25.7/1000 vs 37.7/1000),而人工流产(从2003年的359/1000 - SRR 1.99, 95%CI 1.32-3.00 -降至2015年的147/1000 - SRR 1.11, 95%CI 0.59-2.09 -)和流产率呈下降趋势。结论:这些结果与国际文献一致,可能是由于诊断和治疗机会的进步。这是意大利首个基于人群的研究,基于可靠的癌症诊断信息,分析PAC女性的生育能力和妊娠结局。
{"title":"Fertility and abortion: A population-based comparison between women with cancer and those in childbearing age.","authors":"Alice Maraschini, Edoardo Corsi Decenti, Serena Donati, Silvia Francisci, Tania Lopez, Rosalba Amodio, Fortunato Bianconi, Emanuela Bovo, Rossella Bruni, Marine Castaing, Claudia Cirilli, Rosa Pasqualina De Vincenzo, Giuseppe Furgiuele, Linda Guarda, Silvia Iacovacci, Lucia Mangone, Walter Mazzucco, Anna Melcarne, Elisabetta Merlo, Michael Mian, Giuseppe Sampietro, Giovanni Scambia, Tiziana Scuderi, Ausilia Sferrazza, Fabrizio Stracci, Antonina Torrisi, Vito Trojano, Maria Francesca Vitale, Daniela Pierannunzio","doi":"10.1177/03008916241298810","DOIUrl":"10.1177/03008916241298810","url":null,"abstract":"<p><strong>Objectives: </strong>Concurrence of pregnancy and cancer diagnosis is increasingly frequent in Italy. The study aimed to compare women with pregnancy-associated cancers (PACs) to those of childbearing age, focusing on fertility, induced abortion, and miscarriage.</p><p><strong>Methods: </strong>The population-based study included women aged 15-49 years, both with and without PAC, who were residents in the area covered by the 19 participating Cancer Registries between 2003 and 2015 and identified by individual deterministic linkage with the Hospital Discharge Database.</p><p><strong>Results: </strong>Overall, 2,218,139 obstetrics hospitalizations occurred, covering delivery (75%), induced abortion (14%), and miscarriage (11%). Among 2409 women with PAC, 69% gave birth, 16% had an induced abortion and 15% a miscarriage. Compared with the reference population, the fertility rate in women with PACs was steadily lower (mean values 25.7/1000 vs 37.7/1000), while induced abortion (from 359/1000 - SRR 1.99, 95%CI 1.32-3.00 - in 2003 to 147/1000 - SRR 1.11, 95%CI 0.59-2.09 - in 2015) and miscarriage ratios exhibited a decreasing trend.</p><p><strong>Conclusion: </strong>These results are consistent with international literature and are probably due to advancements in diagnostic and therapeutic opportunities. This is the first Italian population-based study analysing fertility and pregnancy outcomes among women with PAC based on a reliable information on cancer diagnosis.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"71-78"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolving perspectives: Exploring the role of artificial intelligence between clinical practice and health pastoral care. 不断发展的观点:探索人工智能在临床实践和卫生教牧关怀中的作用。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-09 DOI: 10.1177/03008916241299616
Carlo Alfredo Clerici, Andrea Ferrari, Tullio Proserpio

This article analyses the integration of artificial intelligence (AI) in health pastoral care, emphasizing the synergy between technology and spirituality. This paper discusses possible AI applications, highlighting the importance of ethical implementation that respects human interactions. Ethical issues like privacy and empathy are examined, as well as the potential of AI in facilitating collaboration between healthcare professionals and pastoral workers. Finally, it calls for a debate on the responsible use of AI in care contexts.

本文分析了人工智能(AI)在健康教牧关怀中的整合,强调了技术与灵性之间的协同作用。本文讨论了可能的人工智能应用,强调了尊重人类互动的伦理实施的重要性。研究了隐私和同理心等道德问题,以及人工智能在促进医疗保健专业人员和牧养工作者之间合作方面的潜力。最后,它呼吁就在护理环境中负责任地使用人工智能进行辩论。
{"title":"Evolving perspectives: Exploring the role of artificial intelligence between clinical practice and health pastoral care.","authors":"Carlo Alfredo Clerici, Andrea Ferrari, Tullio Proserpio","doi":"10.1177/03008916241299616","DOIUrl":"10.1177/03008916241299616","url":null,"abstract":"<p><p>This article analyses the integration of artificial intelligence (AI) in health pastoral care, emphasizing the synergy between technology and spirituality. This paper discusses possible AI applications, highlighting the importance of ethical implementation that respects human interactions. Ethical issues like privacy and empathy are examined, as well as the potential of AI in facilitating collaboration between healthcare professionals and pastoral workers. Finally, it calls for a debate on the responsible use of AI in care contexts.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"6-10"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). 从实验室到床边的桥梁:肿瘤学转化研究的演变和影响。意大利肿瘤临床组织(GOIRC)的经验。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-02-01 Epub Date: 2024-12-15 DOI: 10.1177/03008916241302919
Benedetta Pellegrino, Filippo Giovanardi, Carmelo Tibaldi, Luca Moscetti, Andrea Vingiani, Luana Calabrò, Gabriele Zoppoli, Stefania Didone, Lorenzo Ferrando, Enrico Franceschi, Renata Todeschini, Michele Tognetto, Alessandro Leonetti, Roberta Minari, Chiara Tommasi, Olga Serra, Luca Boni, Giancarlo Pruneri, Antonino Musolino

The Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) is Italy's first cooperative oncology research group, evolving to conduct academic clinical trials since 1985. With 167 publications and collaborations with national and international partners, GOIRC has significantly impacted clinical practices. The group emphasizes training and has developed robust internal standard operative procedures (SOPs) to enhance data quality. GOIRC is poised to tackle future challenges in translational research, focusing on innovative trial designs, precision medicine, and leveraging different laboratory resources across its 42 units.

Gruppo oncology Italiano di Ricerca Clinica (GOIRC)是意大利第一个合作肿瘤学研究小组,自1985年以来一直开展学术临床试验。GOIRC发表了167篇文章,并与国家和国际合作伙伴开展了合作,对临床实践产生了重大影响。该集团强调培训,并制定了强有力的内部标准操作程序(SOPs),以提高数据质量。GOIRC准备应对未来在转化研究方面的挑战,专注于创新试验设计、精准医学,并在其42个单位中利用不同的实验室资源。
{"title":"Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).","authors":"Benedetta Pellegrino, Filippo Giovanardi, Carmelo Tibaldi, Luca Moscetti, Andrea Vingiani, Luana Calabrò, Gabriele Zoppoli, Stefania Didone, Lorenzo Ferrando, Enrico Franceschi, Renata Todeschini, Michele Tognetto, Alessandro Leonetti, Roberta Minari, Chiara Tommasi, Olga Serra, Luca Boni, Giancarlo Pruneri, Antonino Musolino","doi":"10.1177/03008916241302919","DOIUrl":"10.1177/03008916241302919","url":null,"abstract":"<p><p>The Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) is Italy's first cooperative oncology research group, evolving to conduct academic clinical trials since 1985. With 167 publications and collaborations with national and international partners, GOIRC has significantly impacted clinical practices. The group emphasizes training and has developed robust internal standard operative procedures (SOPs) to enhance data quality. GOIRC is poised to tackle future challenges in translational research, focusing on innovative trial designs, precision medicine, and leveraging different laboratory resources across its 42 units.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"100-105"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Tumori
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1